Company intelligence / Profile preview

NET Recovery

Delaware, United States

Ownership: Private
Employees: ~10
Development stage: Other

Overview

The NET Device is FDA-cleared as a non-pharmaceutical, non-invasive device for reduction of opioid withdrawal symptoms. It is supported by a randomized, sham-controlled, pivotal clinical trial demonstrating strong correlation between one day of active stimulation and 12-week opioid abstinence in patients with high rates of polydrug exposure. The device is available at select Kentucky treatment centers, notably in partnership with Isaiah House. Results show promise as an alternative to medication-assisted treatment for opioid use disorder.

Therapeutic areas: Psychiatry
Modalities: DeviceNon-pharmacological therapyTranscranial alternating current stimulator
Industry: Therapeutic Medical Devices

Partnerships

Isaiah House Treatment CentersWayne State University (Michigan, for clinical trials)

Beyond the preview

Go deeper on NET Recovery.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NET Recovery.

Explore the full profile